登录

Tisenc Medical Closes on ¥80M Series B Financing

Mailman 2020-01-17 17:52

天深医疗
http://www.tisenc.com
企业数据由 动脉橙 提供支持
诊断设备及体外诊断试剂的研发、生产、销售商 | B轮 | 运营中
中国-广东
2021-12-16
万孚生物
查看

According to 36Kr.com, Shenzhen Tisenc Medical Devices Co., Ltd. ("Tisenc Medical"), a provider of POCT (Point Care of internal Care Testing) Chemiluminescence Immunology (CLIA) systems, has completed ¥80 million (US$11.6 million) series B financing, co-led by Elink  CapitaI and TF Capital, with participation from Qiming Venture Partners.


Previously, Tisenc Medical has totally got investment of more than 52 million yuan, including the angel round of tens of millions yuan led by Hangzhou Rock Grass Investment, ¥40 million series A round exclusively from Qiming Venture Partners.


Founded in 2015, Shenzhen Tisenc Medical is a Sino-foreign joint venture. Located in Shenzhen Guangdong, Tisenc Medical is committed to the developing, manufacturing and global sales of CLIA systems. The company provides the products of the CLIA system, high-level POCT system, and molecular diagnostics solutions.


Tisenc Medical has successfully developed the ACCRE system, a single-used automated chemiluminescence immunoassay analyzer, which consists of both the flexible operation of small POCT products and the quality level of chemiluminescence detection systems. Based on the innovative nature of the two, the ACCRE system can satisfy the needs of various customers including emergency departments, STAT laboratories and core laboratories. 


>>>>

About TF Capital


TF Capital focuses on investment in the life sciences industry, including biotechnology, therapeutics & pharmaceuticals, drug delivery, medical device & instruments, and medical service, primarily investing in early-stage companies with high potential.  


Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. 


>>>>
About Qiming Venture Partners


Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。
推荐阅读

妇女获得医疗保健的10个最佳和最差州

Becker's Hospital Review 2024-07-23 02:50

HSS佛罗里达任命首席医疗官

Becker's Hospital Review 2024-07-23 02:49

MetroHealth推出助产服务

Becker's Hospital Review 2024-07-23 02:49

Mailman

共发表文章3245篇

最近内容
查看更多
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

相关公司
查看更多

泰福资本

生命科学领域风险投资公司

立即沟通

启明创投

医疗健康领域投资机构

立即沟通

飞凡创投

半导体、信息技术、生物医药领域投资机构

立即沟通
产业链接
查看更多